Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.75 |
| ▸ | TP53 | P04637 | 1/20 | 0.75 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.75 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.75 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | GABRP | O00591 | 2/20 | 0.43 |
| ▸ | GABRD | O14764 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL15689651 | 1.00 | TSHR (0.75) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL8865128 | 1.00 | TSHR (0.75) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL30577889 | 0.96 | TSHR (0.69) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL8864870 | 0.96 | TSHR (0.69) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL9474609 | 0.92 | TSHR (0.75) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL289218 | 0.92 | TSHR (0.75) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL28825253 | 0.92 | TSHR (0.75) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL8032158 | 0.92 | TSHR (0.75) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Fumaric Acid SCHEMBL28369738 | 0.92 | TSHR (0.75) | TSHRTP53EGLN1EGLN3HCAR2 | |
| Maleic Acid SCHEMBL289217 | 0.92 | TSHR (0.75) | TSHRTP53EGLN1EGLN3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2985023-A1 | PROCESS FOR PREPARING PRASUGREL | Laboratorios Lesvi, S.L. (ES) | 2016-02-17 | — | — | EP | disclosed |
| EP-2736509-B1 | PROCESS FOR PREPARING PRASUGREL | LESVI LABORATORIOS SL (ES) | 2015-09-23 | — | — | EP | disclosed |
| EP-2917213-A1 | CRYSTALLINE FORMS OF (1S)-1-[5-({3-[(2-METHYLPYRIDIN-3-YL)OXY]-5-(PYRIDIN-2-YLSULFANYL)PYRIDIN-2-YL}AMINO)-1,2,4-THIADIAZOL-3-YL]ETHANE-1,2-DIOL | Array Biopharma, Inc. (US) | 2015-09-16 | — | — | EP | disclosed |
| WO-2014074940-A9 | CRYSTALLINE FORMS OF (1S)-1-[5-({3-[(2-METHYLPYRIDIN-3-YL)OXY]-5-(PYRIDIN-2-YLSULFANYL)PYRIDIN-2-YL}AMINO)-1,2,4-THIADIAZOL-3-YL]ETHANE-1,2-DIOL | ARRAY BIOPHARMA INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| EP-2736509-A1 | PROCESS FOR PREPARING PRASUGREL | Laboratorios Lesvi, S.L. (ES) | 2014-06-04 | — | — | EP | disclosed |
| WO-2014074940-A1 | CRYSTALLINE FORMS OF (1S)-1-[5-({3-[(2-METHYLPYRIDIN-3-YL)OXY]-5-(PYRIDIN-2-YLSULFANYL)PYRIDIN-2-YL}AMINO)-1,2,4-THIADIAZOL-3-YL]ETHANE-1,2-DIOL | ARRAY BIOPHARMA INC. (US) | 2014-05-15 | — | — | WO | disclosed |
| EP-2099760-B1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2013-02-20 | — | — | EP | disclosed |
| WO-2013014295-A1 | PROCESS FOR PREPARING PRASUGREL | LABORATORIOS LESVI, S. L. (ES) | 2013-01-31 | — | — | WO | disclosed |
| EP-2099760-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008068268-A1 | ANTIBACTERIAL QUINOLINE DERIVATIVES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | WO | disclosed |
| US-5624922-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1997-04-29 | — | — | US | disclosed |
| US-5380721-A | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents | STERLING WINTHROP INC. (US) | 1995-01-10 | — | — | US | disclosed |
| US-4281010-A | FOR INCREASING BLOOD CIRCULATION | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1981-07-28 | — | — | US | disclosed |
| US-4254269-A | PRECURSERS FOR CARDIOVASCULAR DRUGS | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1981-03-03 | — | — | US | disclosed |
| US-4206213-A | IMPROVING PERIPHERAL AND CEREBRAL CIRCULATION | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DE) | 1980-06-03 | — | — | US | disclosed |